News Related to Halda Therapeutics

Related coverage linked through entity extraction aliases.

FDA Approves Monthly Dosing for J&J's Rybrevant Faspro in EGFR-Mutated Lung Cancer

Feb 25, 2026

The FDA has approved a new monthly dosing schedule for Johnson & Johnson's Rybrevant Faspro combined with Lazcluze for first-line treatment of advanced EGFR-mutated non-small cell lung cancer, allowing patients to transition to monthly dosing as early as week five.

Three Clinical Trial Pipeline Reports Track Progress in Prostate Cancer, NK Cells, and Lung Diseases

Feb 15, 2026

DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.